• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 + T cell responses

tetano

Editor, Senior Moderator
Cell Rep Med


. 2022 Jan 19;3(2):100520.
doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 [SUP]+[/SUP] T cell responses


Hiroshi Ishii[SUP] 1 [/SUP], Takushi Nomura[SUP] 1 [/SUP], Hiroyuki Yamamoto[SUP] 1 [/SUP], Masako Nishizawa[SUP] 1 [/SUP], Trang Thi Thu Hau[SUP] 1 [/SUP], Shigeyoshi Harada[SUP] 1 [/SUP], Sayuri Seki[SUP] 1 [/SUP], Midori Nakamura-Hoshi[SUP] 1 [/SUP], Midori Okazaki[SUP] 1 [/SUP], Sachie Daigen[SUP] 1 [/SUP], Ai Kawana-Tachikawa[SUP] 1 2 3 [/SUP], Noriyo Nagata[SUP] 4 [/SUP], Naoko Iwata-Yoshikawa[SUP] 4 [/SUP], Nozomi Shiwa[SUP] 4 [/SUP], Tadaki Suzuki[SUP] 4 [/SUP], Eun-Sil Park[SUP] 5 [/SUP], Maeda Ken[SUP] 5 [/SUP], Taishi Onodera[SUP] 6 [/SUP], Yoshimasa Takahashi[SUP] 6 [/SUP], Kohji Kusano[SUP] 7 [/SUP], Ryutaro Shimazaki[SUP] 7 [/SUP], Yuriko Suzaki[SUP] 8 [/SUP], Yasushi Ami[SUP] 8 [/SUP], Tetsuro Matano[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8[SUP]+[/SUP] T cell responses. Our results indicate that CD8[SUP]+[/SUP] T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8[SUP]+[/SUP] T cell responses to contribute to COVID-19 containment.

Keywords: CD8+ T cell; COVID-19; intranasal; vaccine; variant; viral vector.
 
Back
Top Bottom